Orum Therapeutic unveils clinical design of HER2 target ‘GSPT1 degrader’ at ASCO
Orum Therapeutics (CEO Lee Seung-joo) presented HER2-targeted GSPT1 (G1 to S phase transition) for patients with advanced solid tumors expressing HER2 at the American Society of Clinical Oncology (ASCO) held in Chicago, USA from 2nd (local time) to 5th. We will disclose the design of a phase 1 clinical trial of protein 1) decomposer ‘ORM-5029 […]
